嵌合抗原受体疗法在血液肿瘤免疫治疗中的研究进展与应用前景

Innovation and prospects of chimeric antigen receptor therapy in hematological malignancies immunotherapy

嵌合抗原受体(CAR)为基础的免疫治疗,发展经历了近25年,它已经从一个新兴的复杂的技术转变成为恶性肿瘤治疗的一种新策略。随着重组DNA技术的不断发展以及对信号传导通路的不断研究深入,CAR技术也在不断革新并开始为临床服务。而CAR疗法以其在血液肿瘤的中独特优势在治疗中不断取得突破,见证了CAR技术成熟的过程。本文主要回顾在血液肿瘤研究中CAR技术的革新、应用现状和前景。

Chimeric antigen receptor-（CAR-） based immunotherapy has been under development for almost 25 years, over which period it has progressed from a new but cumbersome technology to an emerging therapeutic modality for malignant disease. With the development of recombinant DNA technology, as well as signaling pathways continue to study in depth, CAR technology has begun to innovated and be used for clinical services. The CAR therapy in hematological malignancies of its unique advantages in the treatment of hematologic malignancies continue to make breakthroughs, witnessed the CAR technology maturation process. In this paper, we reviewed the technology innovation, application status and prospects of CAR technology in hematological malignancies.